Latest Chiron Corp. Stories
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.
CHICAGO (Reuters) - Chiron Corp. on Thursday said it is recalling and withdrawing its measles, mumps and rubella vaccine, MORUPAR, from Italian and developing world markets because it may be associated with a higher rate of adverse side effects than other such vaccines.
By Susan Heavey WASHINGTON (Reuters) - A test to screen blood, organ and tissue donors for the West Nile virus won U.S. approval after two years of testing in the nation's blood banks, Food and Drug Administration officials said on Thursday. The Procleix WNV Assay was developed by Gen-Probe Inc.
Companies are proposing a change in how they make flu vaccine that they believe will improve the nation's ability to fight the viruses and modernize the process.
By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Unexpectedly high demand for flu shots means some U.S. clinics have run out early, but the country will have plenty of influenza vaccine this year, health officials said on Thursday.
WASHINGTON (Reuters) - The United States has awarded Chiron Corp. a $62.5 million contract to produce millions of doses of vaccine against the H5N1 strain of avian flu, U.S. Health and Human Services Secretary Michael Leavitt said on Thursday.
By Deena Beasley LOS ANGELES (Reuters) - Chiron Corp. on Monday said its U.S. flu vaccine deliveries, and its net income, will fall short of expectations this year due to production delays at its British manufacturing plant.
By Lisa Richwine WASHINGTON (Reuters) - Chiron Corp. may begin shipments within days of its first influenza vaccine since last year's contamination problems that abruptly cut the U.S. supply in half, the company said on Wednesday. U.S.
WASHINGTON (Reuters) - U.S. health officials approved a new flu vaccine on Wednesday in hopes of bolstering supplies after last season's shortage, but said more work is needed before another supplier may be able to resume sales.
NEW YORK (Reuters) - Chiron Corp., which last year suspended U.S. sales of its flu vaccine because of contamination problems at its plant in England, on Wednesday said it hopes to supply the vaccine in the 2005-2006 flu season following a favorable inspection of the plant by U.S. regulators.